Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia

Leukemia(2024)10.1038/s41375-024-02317-4Source: DataRank Database

Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia is a research paper published in Leukemia (2024). On theSindex it has a DataRank of 0. It has been cited 31 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access31 citations

Download PDF

Cite:

Linked data & code

pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 8.87)OA: hybridTopics (61)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Michael Y. Choi ORCID,Huan‐You Wang ORCID,Thomas J. Kipps ORCID,Richard Wong ORCID

Live enrichment

PubMed:39048721 PMC:PMC11286506 OpenAlex:https://openalex.org/W4400959828

NCI NIH HHS

Grant: R01 CA236361

National Institutes of Health

Grant: 5R01CA236361-04

Non-canonical Wnt-Receptor Signaling and Targeted Therapies

FWCI

8.87

Citation Percentile

1.0%

Influential Citations

Citation Trend

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.nature.com/articles/s41375-024-02317-4.pdf

HYBRIDhttps://doi.org/10.1038/s41375-024-02317-4

publisherhttps://www.nature.com/articles/s41375-024-02317-4.pdf

publisherhttps://www.nature.com/articles/s41375-024-02317-4

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39048721

Fields of Study

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune DisordersMedicine03 medical and health sciences0302 clinical medicineAgammaglobulinaemia Tyrosine KinaseLeukemia, Lymphocytic, Chronic, B-CellHumansDrug Resistance, NeoplasmProtein Kinase InhibitorsMutationFemalePyrimidinesMaleAgedMiddle Aged

MeSH Terms

Agammaglobulinaemia Tyrosine KinaseAgedFemaleHumansMaleMiddle AgedMutationPyrimidinesLeukemia, Lymphocytic, Chronic, B-CellDrug Resistance, NeoplasmProtein Kinase Inhibitors

Keywords

Bruton's tyrosine kinaseChronic lymphocytic leukemiaTyrosine kinaseImmunologyIbrutinibCancer researchMedicineLeukemiaHematologyMutationBiologyInternal medicineGeneticsGeneReceptorMaleLetterB-CellDrug Resistance610500Middle AgedLeukemia, Lymphocytic, Chronic, B-CellLymphocyticPyrimidinesDrug Resistance, NeoplasmAgammaglobulinaemia Tyrosine KinaseNeoplasmHumansFemaleChronicProtein Kinase InhibitorsAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being